Australian Family Physician
Australian Family Physician


Volume 43, Issue 3, March 2014

Necrobiosis lipoidica

Daniel Rodriguez-Muñoz Andrés González-Garcia Emiliano Grillo Pedro Jaén Olasolo
Download article
Cite this article    BIBTEX    REFER    RIS

Necrobiosis lipoidica presents with a distinctive appearance making it an important clinical diagnosis.
To describe a case of necrobiosis lipoidica in a patient with type 1 diabetes mellitus, and to discuss differential diagnoses and management.
Necrobiosis lipoidica is most commonly found on the shins, presenting as a well-defined plaque. Management is challenging and options are discussed. Avoiding ulceration is a key concern.
Figure 1a. Brownish, sharply demarcated, indurated plaque on the right shin.

Figure 1a. Brownish, sharply demarcated, indurated plaque on the right shin. Three similar smaller lesions can be observed on the left shin

Figure 1b. A close-up view of the plaque.

Figure 1b. A close-up view of the plaque. Telangiectatic vessels can be observed on a yellow background

The lesions observed in the patient are typical, which allowed us to make the clinical diagnosis of necrobiosis lipoidica (NL). NL usually presents as small papules or nodules that expand sharply into red-brown-to-yellow plaques that are typically located on the anterior pretibial region. The lesions have a violaceous, irregular border that may be raised and indurated. Commonly, telangiectasias are visible, taking on the characteristic ‘glazed-porcelain’ sheen.

In 1932 Urbach coined the term necrobiosis lipoidica diabeticorum for this disease because it was first described in patients with DM. As it can also appear in non-diabetic patients, the term was shortened to NL. Mean age of onset is 30 years and the incidence is three times higher in women. The prevalence of NL has been reported in different studies to be around 1–2% of patients with type 1 DM.1

Although lacking complete concordance, NL has a solid association with DM and remains a valid marker of the disease. About one-third of patients with NL have DM, and about two-thirds have glucose tolerance abnormalities.2 However, the presence of this skin lesion does not correlate with the level of glycaemic control.1

Differential diagnosis

Granuloma annulare (GA) is a relatively common disorder. Superficial annular lesions can resemble NL. However, GA lesions lack the typical fatty appearance of the yellow NL plaques.

Erythema nodosum is an inflammation of the fat cells in the subcutaneous tissue. Erythema nodosum presents with bilateral, tender, erythematous nodules that lack epidermal change, atrophy or ulceration.

Necrobiotic xanthogranuloma is a very rare, chronic, progressive granulomatous disorder that manifests as yellowish plaques and nodules that can resemble NL. However, in contrast to NL, necrobiotic xanthogranuloma typically presents periorbitally and is associated with paraproteinaemia.3

Sarcoidosis is mainly a diagnosis of exclusion. Although the hallmark of sarcoidosis is a granulomatous plaque, cutaneous lesions rarely ulcerate or show atrophy.

How to make the diagnosis

Diagnosis of NL is usually made clinically, but a skin biopsy might be necessary in atypical lesions. Laboratory findings are unhelpful in the diagnosis of NL. Given the relationship between NL and impaired glucose regulation, patients should be screened for diabetes.4


At present, only small, uncontrolled trials and case reports provide guidance for the management of this disorder. Most authors consider the early application of potent topical glucocorticoids, monitoring for excessive atrophy, as first-line treatment (evidence level: C – expert opinion).5 Intralesional injections of glucocorticoids in the active border have been reported to be useful, although the risk of ulceration with this treatment modality should be considered (evidence level: C).5

Isolated reports support the use of topical retinoids and topical psoralen combined with ultraviolet A (PUVA) treatment.6,7 Recently, photodynamic therapy has been described as another option for the management of NL.8

Calcineurin inhibitors have also been used successfully in some cases. Their effectiveness seems to be higher in ulcerated lesions.9 Similarly, cyclosporine (2.5 mg/kg/day)10 has also been used successfully in ulcerated lesions. The mechanism of action is similar to that of calcineurin inhibitors, preventing T-cell activation.

Aspirin and dipyridamole have produced variable results.11 Other drugs that have been used are clofazimine,12 ticlopidine13 and nicotinamide.14

Various types of laser treatment have been described (pulsed dye laser, CO2 fractional laser);15,16 however, scientific evidence for the effectiveness of these treatments is still too scarce to formally recommend them.

Unfortunately, none of the proposed treatments has achieved a sustained effective response. Surgical excision down to the fascia and split thickness skin grafting remain as the last treatment option for recalcitrant ulcers in NL.17

In some cases, owing to the benign nature of the lesions, a conservative ‘wait and see’ strategy is also acceptable. In all patients, the focus should be on prevention of ulcers. In the event of ulceration, wound care principles for all diabetic ulcers apply.


The main and most serious complication is ulceration, which occurs on the legs in about one third of NL cases. In addition, a few cases of squamous cell carcinoma on chronic ulcerative lesions of NL have been described.18


Given the risk of ulceration, we decided to treat our patient with 0.1% topical tacrolimus. Clinical improvement was slight but the lesions remained stable. After a 1-year follow up, the disease is controlled and has not become ulcerated.

Our case shows a patient with DM who developed typical lesions of NL. The therapeutic management of these lesions is difficult. Our efforts should focus on preventing ulceration and if possible improve aesthetic appearance.

Competing interests: None.
Provenance and peer review: Not commissioned; externally peer reviewed.

  1. Pavlovic MD, Milankovic T, Dinic M, et al. The prevalence of cutaneous manifestations in young patients with type 1 diabetes mellitus. Diabetes Care 2007;30:1964–67. Search PubMed
  2. Hawryluk E, Izikson L, English J. Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions. Am J Clin Dermatol 2010;11:171–81. Search PubMed
  3. Lam K, Brownstein S, Jordan DR, van der Jagt R, Jastrzebski A, Dionne MA. Bilateral Necrobiotic Xanthogranuloma of the Eyelids Followed by a Diagnosis of Multiple Myeloma 20 Years Later. Ophthal Plast Reconstr Surg 2012 Dec 14 [Epub ahead of print]. Search PubMed
  4. Muller SA, Winkelmann RK. Necrobiosis lipoidica diabeticorum: a clinical and pathological investigation of 171 cases. Arch Dermatol 1966;93:272–81. Search PubMed
  5. Erfurt-Berge C, Seitz AT, Rehse C, Wollina U, Schwede K, Renner R. Update on clinical and laboratory features in necrobiosis lipoidica: a retrospective multicentre study of 52 patients. Eur J Dermatol 2012;22:770–75. Search PubMed
  6. Heymann WR. Necrobiosis lipoidica treated with topical tretinoin. Cutis 1996;58:53–54. Search PubMed
  7. De Rie MA, Sommer A, Hoekzema R, Neumann HA. Treatment of necrobiosis lipoidica with topical psoralen plus ultraviolet A. Br J Dermatol 2002;147:743–47. Search PubMed
  8. Heidenheim M, Jemec GB. Successful treatment of necrobiosis lipoidica diabeticorum with photodynamic therapy. Arch Dermatol 2006;142:1548–50. Search PubMed
  9. Clayton TH, Harrison PV. Successful treatment of chronic ulcerated necrobiosis lipoidica with 0.1% topical tacrolimus ointment. Br J Dermatol 2005;152:581–82. Search PubMed
  10. Stanway A, Rademaker M, Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporine. Australas J Dermatol 2004;45:119–22. Search PubMed
  11. Eldor A, Diaz EG, Naparstek E. Treatment of diabetic necrobiosis with aspirin and dipyridamole. N Engl J Med 1978;298:1033. Search PubMed
  12. Mensing H. Clofazimine--therapeutic alternative in necrobiosis lipoidica and granuloma anulare. Hautarzt 1989;40:99–103. Search PubMed
  13. Rhodes EL. Necrobiosis lipoidica treated with ticlopidine. Acta Derm Venereol 1986;66:458. Search PubMed
  14. Handfield-Jones S, Jones S, Peachey R. High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol 1988;118:693–96. Search PubMed
  15. Moreno-Arias GA, Camps-Fresneda A. Necrobiosis lipoidica diabeticorum treated with the pulsed dye laser. J Cosmet Laser Ther 2001;3:143–46. Search PubMed
  16. Buggiani G, Tsampau D, Krysenka A, De Giorgi V, Hercogová J. Fractional CO2 laser: a novel therapeutic device for refractory necrobiosis lipoidica. Dermatol Ther 2012;25:612–14. Search PubMed
  17. Owen CM, Murphy H, Yates VM. Tissue-engineered dermal skin grafting in the treatment of ulcerated necrobiosis lipoidica. Clin Exp Dermatol 2001;26:176–78. Search PubMed
  18. Lim C, Tschuchnigg M, Lim J. Squamous cell carcinoma arising in an area of long-standing necrobiosis lipoidica. J Cutan Pathol 2006;33:581–83. Search PubMed
Download article PDF


Australian Family Physician RACGP

Printed from Australian Family Physician - https://www.racgp.org.au/afp/2014/march/necrobiosis-lipoidica
© The Australian College of General Practitioners www.racgp.org.au